High-dose Topotecan treatment for recurrent retinoblastoma with vitreous seeds

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of high-dose Topotecan, a chemotherapeutic agent, to treat patients with retinoblastoma who have recurrent or refractory vitreous seeds. The study aims to improve anti-tumor activity while minimizing side effects associated with traditional chemotherapy. Patients eligible for this trial include those with specific genetic mutations and active tumors in one eye, who wish to preserve their eye despite the recommendation for enucleation. The trial will also involve the collection of aqueous humor and the use of electroretinograms to assess retinal function.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with retinoblastoma with a somatic mutation of the gene RB1 and active tumor in a single eye, or germinal mutation of RB1 with active tumor/s in an eye and the contralateral eye unaffected, enucleated or without tumor activity. In both cases, relapsed or refractory vitreous seeding with the use of systemic, intraarterial or intravitreal chemotherapy or radiotherapy, in accordance with the availability at his/her referral site, in whom enucleation is the only recommended treatment under opinion of the medical team treating the case at the originating referral site. But the patient has a strong desire to preserve the eye.
2. Normal renal function: serum creatinine: \< 45 μmol/L (0-2 years); \< 57 μmol/L (3-6 years); \< 60 μmol/L (7-10 years); \< 80 μmol/L (11-13 years).
3. Normal Hepatic function: serum ALT: \< 0,52 μkat/L (de 9 months -12 years); serum AST: 61-80 g/L (8 months-5 years); 63-83 g/L (5-9 years); 63-82 g/L (9-12 years).
4. Adequate marrow reserve manifested in an absolute neutrophil count \> 1000 / mm3, platelets \> 100,000 / mm3 and hemoglobin\> 8 g / dl, without transfusional or cytokine support at least one month prior to study entry.
5. Age greater than 1 year and less than 12 years at the time of inclusion in the study.
6. Sign the informed consent form and be willing to follow up at the specified time.

Exclusion Criteria:

1. Presence of factors that require immediate enucleation of the affected eye such as glaucoma, rubeosis iridis, anterior chamber involvement.
2. Comorbidities: Uncontrolled epilepsy with anticonvulsant treatment, cardiac disease not compensated by treatment.
3. Active Infections.
4. Other chronic or active acute diseases that under the criterion of the researcher were an exclusion criterion.
5. History of having received attenuated or live vaccines in the 30 days prior to inclusion in the study.
6. Any cause of Immunosuppression.
7. Trilateral Retinoblastoma.
8. Extraocular spread.
9. History of having received treatment for retinoblastoma with chemotherapy or radiation therapy by any means within 30 days prior to inclusion in the study.
10. Patients who can not complete the study procedures for reasons psychologically or socially

Where it's running

• Fudan Eye & ENT Hospital
  Shanghai, China, China Recruiting

Study contacts

• Study coordinator: Kang Xue, MD
• Email: xuekang@foxmail.com
• Phone: +86 (021) 64377134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Linking RB1 genetic changes to eye tumors and metastasis

  We will use targeted long-read genetic sequencing on people with retinoblastoma to see if specific RB1 mutations match tumor features and the risk of spread.

  Recruiting University of Washington · Seattle, Washington · NCT06725173

• Treatment for advanced retinoblastoma using a chemoplaque

  This study is testing a new treatment using a special chemotherapy patch for young children with advanced retinoblastoma to see if it helps fight the cancer while keeping their vision safe.

  Recruiting at 2 sites Phase 2 Targeted Therapy Technologies, LLC · New York, New York and 1 other locations · NCT06679634

• New treatment for children with hard-to-treat retinoblastoma

  This study is testing a new drug for children with hard-to-treat eye cancer to see if it works better and has fewer side effects than standard chemotherapy.

  Recruiting Early Phase 1 Eye & ENT Hospital of Fudan University · Shanghai · NCT06424301

• Understanding the incidence and outcomes of trilateral retinoblastoma

  This study looks at how common trilateral retinoblastoma is and how well patients survive, comparing data from different countries to see if there are differences based on income levels.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06367530

• Chemotherapy for high-risk retinoblastoma after eye removal

  This study is testing if giving chemotherapy after removing the eye can help prevent high-risk retinoblastoma from coming back in children with Stage I disease.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT05080010

• Collecting and analyzing eye fluid from children with retinoblastoma

  This study is trying to see if collecting eye fluid from children with retinoblastoma can help find important markers for better treatment and understanding of the disease.

  Recruiting at 9 sites Children's Hospital Los Angeles · Phoenix, Arizona and 8 other locations · NCT04959097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.